Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 3,844,000 | 9,407,000 | 18,620,000 | 5,001,000 | 4,063,000 |
Marketable Securities | 242,000 | 203,000 | 155,000 | 1,124,000 | 397,000 |
Receivables | 5,182,000 | 5,249,000 | 3,248,000 | 3,418,000 | 3,586,000 |
Inventories | 3,796,000 | 3,601,000 | 2,434,000 | 2,599,000 | 2,643,000 |
Other current assets | 0 | 20,000 | 513,000 | 105,000 | 892,000 |
TOTAL | $14,632,000 | $20,147,000 | $26,776,000 | $14,155,000 | $13,556,000 |
Non-Current Assets | |||||
PPE Net | 7,563,000 | 7,607,000 | 5,705,000 | 5,730,000 | 5,935,000 |
Investments And Advances | 897,000 | 883,000 | 2,947,000 | 4,041,000 | 229,000 |
Intangibles | 42,196,000 | 45,493,000 | 12,222,000 | 15,200,000 | 16,265,000 |
Other Non-Current Assets | 1,885,000 | 2,120,000 | 5,016,000 | 2,121,000 | 5,222,000 |
TOTAL | $52,541,000 | $56,103,000 | $25,890,000 | $27,092,000 | $27,651,000 |
Total Assets | $67,173,000 | $76,250,000 | $52,666,000 | $41,247,000 | $41,207,000 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | 7,000 | 508,000 | 3,000 | 3,000 | 55,000 |
Accounts payable and accrued liabilities | 2,975,000 | 2,402,000 | 1,178,000 | 1,081,000 | 1,064,000 |
Accrued Expenses | 1,182,000 | 1,187,000 | 752,000 | 746,000 | 776,000 |
Other current liabilities | N/A | N/A | 245,000 | 373,000 | 680,000 |
TOTAL | $9,012,000 | $8,912,000 | $6,660,000 | $9,186,000 | $10,467,000 |
Non-Current Liabilities | |||||
Long Term Debt | 19,359,000 | 27,210,000 | 20,681,000 | 5,871,000 | 3,393,000 |
Other Non-Current Liabilities | 8,080,000 | 9,030,000 | 4,608,000 | 4,864,000 | 5,708,000 |
TOTAL | $27,439,000 | $36,240,000 | $25,289,000 | $10,735,000 | $9,101,000 |
Total Liabilities | $36,451,000 | $45,152,000 | $31,949,000 | $19,921,000 | $19,568,000 |
Shareholders' Equity | |||||
Shares Outstanding, K | 1,756,470 | 1,746,334 | 1,727,998 | 1,473,242 | 1,508,978 |
Common Shares | 23,512,000 | 23,206,000 | 13,027,000 | 12,734,000 | 12,383,000 |
Retained earnings | 24,560,000 | 23,978,000 | 25,565,000 | 25,757,000 | 22,874,000 |
Other shareholders' equity | -7,388,000 | -5,861,000 | -7,084,000 | -6,543,000 | -4,940,000 |
TOTAL | $30,722,000 | $31,098,000 | $20,717,000 | $21,326,000 | $21,639,000 |
Total Liabilities And Equity | $67,173,000 | $76,250,000 | $52,666,000 | $41,247,000 | $41,207,000 |